Items where authors include "Seligmann, JF"

Article

Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029

Williams, CJM, Fish, R, Akerman, L et al. (4 more authors) (2022) Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: real life experience of implementing FOxTROT. Colorectal Disease. ISSN 1462-8910

Seligmann, JF, Fisher, DJ, Brown, LC et al. (19 more authors) (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 39 (33). pp. 3705-3715. ISSN 0732-183X

Adams, RA, Fisher, DJ, Graham, J et al. (19 more authors) (2021) Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology. JCO.21.01436-JCO.21.01436. ISSN 0732-183X

Taylor, JC orcid.org/0000-0002-2518-5799, Swinson, D, Seligmann, JF et al. (8 more authors) (2021) Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: can a regional intervention promote national change? International Journal of Cancer, 148 (4). pp. 845-856. ISSN 0020-7136

Seligmann, JF, Wright-Hughes, A orcid.org/0000-0001-8839-6756, Pottinger, A et al. (10 more authors) (2020) Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial. Clinical Oncology, 32 (10). pp. 656-664. ISSN 0936-6555

Seligmann, JF, Elliott, F, Richman, S orcid.org/0000-0003-3993-5041 et al. (8 more authors) (2020) Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. Annals of Oncology, 31 (8). pp. 1021-1029. ISSN 0923-7534

Baaten, ICPA, West, NP orcid.org/0000-0002-0346-6709, Quyn, AJ et al. (2 more authors) (2020) Colorectal cancer peritoneal metastases: Biology, treatment and next steps. EJSO - European Journal of Surgical Oncology, 46 (4). pp. 675-683. ISSN 0748-7983

Seligmann, JF, Hatch, AJ, Richman, SD orcid.org/0000-0003-3993-5041 et al. (8 more authors) (2018) Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncology, 4 (4). pp. 564-568. ISSN 2374-2437

Seligmann, JF and Seymour, MT orcid.org/0000-0002-2441-9629 (2017) Editorial: Use of Gene Expression Profiles to Distinguish Molecular Subtypes in Colorectal Cancer: Progression Toward Primetime. JNCI: Journal of the National Cancer Institute, 109 (7). djx019. ISSN 0027-8874

Seligmann, JF, Fisher, D, Smith, CG et al. (9 more authors) (2017) Investigating the poor outcomes of BRAF - mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology, 28 (3). pp. 562-568. ISSN 0923-7534

Seligmann, JF, Elliott, F, Richman, SD et al. (7 more authors) (2016) Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. JAMA oncology, 2 (5). pp. 633-642. ISSN 2374-2437

Seymour, MT, Brown, SR, Middleton, G et al. (18 more authors) (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet Oncology, 14 (8). 749 - 759. ISSN 1470-2045

Conference or Workshop Item

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Adams, R, Fisher, D, Graham, J et al. (13 more authors) (2021) Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. In: 2021 ASCO Annual Meeting I, 04-08 Jun 2021, Online.

Seligmann, JF and Grp, FC (2020) FOxTROT: neoadjuvant FOLFOX chemotherapy with or without panitumumab (Pan) for patients (pts) with locally advanced colon cancer (CC). In: 2020 ASCO Annual Meeting I, 29-31 May 2020, Online.

Proceedings Paper

Shiu, K-K, Seligmann, JF orcid.org/0000-0003-4379-6005, Graham, J et al. (15 more authors) (2022) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting I, 03-07 Jun 2022, Chicago, USA. American Society of Clinical Oncology .

Williams, C, Emmerson, J, Beggs, AD et al. (12 more authors) (2022) A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442). In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting, 03-07 Jun 2022, Online & Chicago, IL, USA. American Society of Clinical Oncology .

Seligmann, JF, Fisher, D, Smith, CG et al. (8 more authors) (2016) Exploring outcomes of RAS-mutant (RAS mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 03-07 Jun 2016, Chicago, Il. American Society of Clinical Oncology .

Seligmann, JF, Fisher, D, Elliott, F et al. (8 more authors) (2015) Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .

Seligmann, JF, Elliott, F, Jacobs, B et al. (10 more authors) (2015) HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .